Champions Oncology (CSBR) Net Cash Flow (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Net Cash Flow of -$1.4 million in Q1 2026, up 23.22% quarter-over-quarter from -$1.8 million in Q4 2025, and down 410.04% on a YoY basis from $448000.0 in Q1 2025.
Champions Oncology (CSBR) Net Cash Flow (2010 - 2026) Analysis & Trends
Champions Oncology's Net Cash Flow history runs 17 years deep, the most recent figure standing at -$1.4 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 410.04% year-over-year to -$1.4 million; the TTM figure through Jan 2026 stood at $3.9 million (up 410.03% YoY), while the FY2025 annual figure was $7.2 million, up 195.56% from the prior year.
- Net Cash Flow was -$1.4 million for Q1 2026 at Champions Oncology, up from -$1.8 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $6.6 million in Q2 2025 to a low of -$5.2 million in Q3 2023.
- Historically, Net Cash Flow has averaged $138000.0 across 5 years, with a median of $274000.0 in 2024.
- Biggest YoY gain for Net Cash Flow was 455.84% in 2025; the steepest drop was 1210.87% in 2025.
- A 5-year view of Net Cash Flow shows it stood at $2.8 million in 2022, then sank by 76.73% to $644000.0 in 2023, then sank by 121.43% to -$138000.0 in 2024, then slumped by 1210.87% to -$1.8 million in 2025, then rose by 23.22% to -$1.4 million in 2026.
- The last three Net Cash Flow figures came in at -$1.4 million (Q1 2026), -$1.8 million (Q4 2025), and $540000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 664,983.53 |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | -1.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -1.39 Mn |
| Jan 31, 2026 | -1.39 Mn |
| Oct 31, 2025 | -1.81 Mn |
| Oct 31, 2025 | -1.81 Mn |
| Jul 31, 2025 | 540,000.00 |
| Jul 31, 2025 | 540,000.00 |
| Apr 30, 2025 | 6.58 Mn |
| Apr 30, 2025 | 6.58 Mn |
| Jan 31, 2025 | 448,000.00 |
| Jan 31, 2025 | 448,000.00 |
| Oct 31, 2024 | -138,000.00 |
| Oct 31, 2024 | -138,000.00 |
| Jul 31, 2024 | 274,000.00 |
| Jul 31, 2024 | 274,000.00 |
| Apr 30, 2024 | -1.85 Mn |
| Apr 30, 2024 | -1.85 Mn |
| Jan 31, 2024 | -1.05 Mn |
| Jan 31, 2024 | -1.05 Mn |
| Oct 31, 2023 | 644,000.00 |
| Oct 31, 2023 | 644,000.00 |